Business Wire

VALBIOTIS Announces Additional Positive Results From the Phase IIA Clinical Study of VALEDIA®, the First Product Proven Effective in People With Prediabetes, in Lipid Metabolism and Arterial Hypertension

Share

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190902005205/en/

VALBIOTIS pipeline (Graphic: VALBIOTIS)

VALBIOTIS pipeline (Graphic: VALBIOTIS)

VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced additional positive results from its Phase IIA clinical study2 of VALEDIA® on four parameters which were among the secondary endpoints of the study: blood triglyceride levels, Fatty Liver Index, (fat accumulation in the liver), blood LDL cholesterol levels, and arterial hypertension.

Topline data from the study were published on 3 July 20191, which showed a significant reduction in hyperglycemia, body weight and waist size compared to placebo. The entire Phase IIA clinical study has therefore demonstrated the efficacy of VALEDIA® on various abnormalities in carbohydrate and lipid metabolism.

Professor Jean-Marie BARD, Hospital Practitionner and Professor of Fundamental and Clinical Biochemistry at the University of Nantes, scientific expert for the study, commented, "The full results clearly demonstrate a positive effect on the entire clinical profile: hyperglycemia, hypertriglyceridemia, hepatic steatosis, overweight and abdominal obesity, hypercholesterolemia and arterial hypertension. These risk factors, contribute to an increased risk of type 2 diabetes, cardiovascular disease and liver diseases such as NASH."

Murielle CAZAUBIEL, Director of Development and Medical Affairs, and member of the VALBIOTIS Executive Board, explained, "Today, we are presenting very compelling data which demonstrates the global efficacy of TOTUM-63, active substance of VALEDIA® and its action on the metabolic profile as a whole. This is excellent news for our priority to reduce the risk of type 2 diabetes in prediabetic patients.

We will soon be launching two concurrent Phase IIB studies in prediabetic patients (last studies), as announced previously. Our medium-term strategy is also clear: the significant lipid-lowering effect of VALEDIA® bodes extremely well for the reduction of non-alcoholic fatty liver, a risk condition for developing NASH. This will be the main focus of another Phase IIB clinical study. These results have opened up new opportunities for TOTUM-63 in the future, in the field of hypertension, for example."

Additional results from the Phase IIA clinical study of VALEDIA® in lipid metabolism and arterial hypertension

The international Phase IIA clinical study evaluated the efficacy of VALEDIA® on carbohydrate and lipid metabolism. The subjects included presented with prediabetes, abdominal obesity and hypertriglyceridemia, which were not treated according to current guidelines, as well as a high fatty liver index and high blood pressure. Hypoglycemic, lipid-lowering or hypotensive treatments were excluded. Lipid and hypertension parameters were secondary criteria in the study.

Methodology

This was a multicenter, randomized, placebo-controlled, double-blind study. Subjects received a daily dose of 5 grams of VALEDIA®, compared to 5 grams of placebo for subjects in the control group, over a 6-month period. Diet and physical activity levels remained the same throughout the study in both groups. Analyses were based on 51 subjects, 13 in the placebo group and 38 in the VALEDIA® group.

Characteristics of participants at the beginning of the study

35 women, 16 men; average age: 57.1 years.

 

Average value of participants
at the beginning of the study (baseline)

Maximum values
recommended for adults

Body Mass Index (BMI)

31.3 kg/m2

25 kg/m2 (overweight threshold)

Glycemic parameters

- Fasting blood glucose

1.26 g/L

1.00 g/L (prediabetes threshold*)

- Blood glucose level at 2 hours (OGTT)

1.85 g/L

1.40 g/L (prediabetes threshold)

Lipid parameters

- Fasting triglycerides

1.78 g/L

1.50 g/L (men) and 1.20 g/L (women)

- Fatty Liver Index

73.34

60 (threshold for very high probability of steatosis)

Systolic blood pressure

131 mmHg

130 mmHg (in the case of metabolic syndrome) or 140 mmHg

*According to the American Diabetes Association (1.10 g/L according to the WHO)

Results in lipid metabolism:

VALEDIA® significantly reduced two metabolic parameters for lipids, compared to placebo: triglyceridemia (p< 0.01) and Fatty Liver Index (p<0.001).

 

Triglycerides

 

Variation at 6 months (g/L)

Variation of VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 0.15 (± 0.15)

- 32.2%

VALEDIA® (n=38 subjects)

- 0.31 (± 0.10)

 

Average values (± SEM)

 

 

 

 

 

 

Fatty liver index

 

Variation at 6 months

Variation of VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 5.64 (± 3.06)

- 18.7%

VALEDIA® (n=38 subjects)

- 4.66 (± 1.51)

 

Average values (± SEM)

 

Compared to placebo, VALEDIA® also significantly reduced blood LDL cholesterol levels (p<0.05).

 

 

LDL cholesterol

 

Variation at 6 months

Variation of VALEDIA®
vs placebo 3

Placebo (n=13 subjects)

+ 0.08 (± 0.07)

- 11.7%

VALEDIA® (n=38 subjects)

- 0.07 (± 0.04)

 

Average values (± SEM)

 

Results in arterial hypertension:

Compared to placebo, VALEDIA® significantly reduced systolic blood pressure (p<0.01) in the total study population.

 

Systolic blood pressure

 

Variation at 6 months (mmHg)

Variation of VALEDIA®
vs placebo 4

Placebo (n=13 subjects)

+ 7.54 (± 3.29)

- 10.57 mmHg

VALEDIA® (n=38 subjects)

- 3.03 (± 1.23)

 

Average values (± SEM)

 

Additional analyses were conducted on a subgroup, involving all subjects at the beginning of the study with systolic blood pressure levels higher than 130 mmHg, the threshold for hypertension in cases of metabolic syndrome. The difference in the changes measured at the end of the study was significant (p <0.001) and reached 18.9 mmHg in favor of the VALEDIA® group (n = 18) compared to placebo (n = 8).

 

Systolic blood pressure

 

Variation at 6 months (mmHg)

Variation of VALEDIA®
vs placebo 4

Placebo (n=8 subjects)

+ 10.75 (± 4.31)

- 18.86 mmHg

VALEDIA® (n=18 subjects)

- 8.11 (± 2.62)

 

Average values (± SEM)

 

Sébastien PELTIER, CEO of VALBIOTIS concluded, "The additional results from this Phase IIA clinical study have far exceeded our expectations. This data demonstrates the efficacy of VALEDIA® for its primary indication, the reduction of risk of developing type 2 diabetes in people with prediabetes. What's more, this study demonstrates the comprehensive action of VALEDIA® on metabolic syndrome. This is a major asset for VALBIOTIS, opening up new prospects in promising markets, such as in the field of non-alcoholic fatty liver or arterial hypertension, which will be a major focus point for future developments. In terms of our commercial strategy, these excellent results will naturally give new impetus to our negotiations with potential partners".

About TOTUM-63, the active ingredient of VALEDIA®

Prediabetes is a growing public health problem worldwide, which is recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation, among others. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.

VALEDIA® is the first clinically validated product specifically designed to help prediabetics reduce their risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active ingredient TOTUM-63, a unique and patented combination of 5 plant extracts that act in synergy to target the physiopathological mechanisms of type 2 diabetes.

TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the first international randomized, placebo-controlled study showed that in patients with prediabetes, TOTUM-63 reduces fasting blood glucose and blood glucose at 2 hours, two risk factors of type 2 diabetes. In these subjects, who also presented with hypertriglyceridemia and abdominal obesity, TOTUM-63 significantly reduced body weight, waist circumference, blood triglycerides, Fatty Liver Index, blood cholesterol levels, and arterial hypertension.

The published Phase IIA study results and all key information about the Company are presented in an updated corporate presentation, available at the following link: www.valbiotis.com/documents/

ABOUT VALBIOTIS

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.

VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).

VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.

Find out more about VALBIOTIS:
www.valbiotis.com

Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL

This press release contains forward-looking statements about VALBIOTIS' objectives, based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R19-030). The document is available on the Company’s website (www.valbiotis.com). This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.

1 VALBIOTIS published the methodology and "Topline" results for the Phase IIA study in a press release on 3 July 2019: https://www.valbiotis.com/app/uploads/2019/07/2019-06-21-PR_VALBIOTIS_PHASEIIA-VALEDIA.pdf
2 ID-RCB Number: 2016-A00484-47
3 Difference between averages of individual variations expressed in %
4 Difference between averages of individual variations

Contact information

VALBIOTIS  
CORPORATE COMMUNICATION  
Carole Rocher /  
Marc Delaunay  
+33 5 46 28 62 58  
medias@valbiotis.com

FINANCIAL COMMUNICATION  
ACTIFIN  
Stéphane Ruiz  
+33 1 56 88 11 14  
sruiz@actifin.fr

MEDIA RELATIONS  
MADIS PHILEO  
Guillaume De Chamisso  
+33 6 85 91 32 56  
guillaume.dechamisso@madisphileo.com

UNITED STATES  
SOLEBURY TROUT  
Rebecca John / Patrick Till  
+1 646 378 2935  
rjohn@troutgroup.com  
ptill@troutgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Meet Global Exhibitors and Hear from World-Renowned Speakers at CHTF201914.11.2019 04:00:00 EETPress release

The 21st China Hi-Tech Fair (CHTF2019), themed “invigorating the Great Bay Area through opening up and innovation,” opened on November 13-17, 2019 in Shenzhen, China. Visitors will meet leading local and global hi-tech enterprises as well as Nobel laureate speakers. Featuring the technological achievements in the Guangdong-Hong Kong-Macau Greater Bay Area, CHTF2019 created an online VR exhibition hall for key exhibitors, especially enterprises from the Area, to help them reach a larger audience apart from on-site visitors. Chamtent Technology (Booth: 2G69), focusing on smart household products, has developed a series of environment-friendly products such as smart trash cans, as well as the HyperLink Automatic Waste Recycled System to be applied in modern residential communities to make life more effective. ISUKE Technology (Booth: 2D31) focuses on health management for both professional healthcare institutions and individuals. Its innovative health information collection devices (inclu

Juan Carro Arbelo Appointed as Regional Manager for Insurance, Iberia13.11.2019 22:00:00 EETPress release

Starr Insurance Companies today announced the appointment of Juan Carro Arbelo as Regional Manager for Insurance, Iberia, subject to regulatory approval. Mr. Carro is responsible for the development of Starr’s commercial lines presence across the Iberian Peninsula, effective November 4, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005709/en/ (Photo: Business Wire) “Juan brings more than 22 years of insurance industry experience working on both the brokerage and carrier sides of the business,” stated Maurice R. Greenberg, Chairman and CEO, Starr Insurance Companies. “His extensive background in developing and establishing lines of business will aid in growing new channels for Starr across Iberia.” The new role strengthens Starr’s European operations, which now includes the UK, Benelux countries, Central and Eastern Europe and the Iberian Peninsula. The European region offers a wide breadth of Starr’s insurance p

SNCF Selects Klas Telecom TRX R6 for French National Rail Network13.11.2019 20:00:00 EETPress release

Klas Telecom today announced that, together with their French partner Seolane Innovation, they have entered into an agreement with France’s national rail operator, SNCF to supply the TRX R6 Connected Transportation Platform for implementation on board SNCF’s trains. This agreement comes as the result of a highly competitive public tender in which SNCF sought to acquire an onboard connectivity solution to provide improved operational and passenger-centric services. Julien Baratier, the Project Manager for SNCF commented, "Through this tender process, we sought to develop our onboard technical solution to fulfil our customer requirements in terms of train connectivity and onboard services. Although new partners for us, Klas Telecom and Seolane have demonstrated their technical commitment by offering a modular, flexible and performing solution. We are very excited to now be working together on a first rollout on regional trains to support a CCTV service." Wilfrid Rouger, CEO of Seolane In

U.S. Ambassador Johnson and UK’s Sir Nicholas Soames to join Bermuda Premier at Executive Forum in London13.11.2019 19:17:00 EETPress release

The United States Ambassador to the United Kingdom (UK), Robert Wood Johnson, and the UK’s Rt. Hon. Sir Nicholas Soames, former defence minister and former Conservative Member of Parliament for Mid Sussex, will join Bermuda’s Premier, the Hon. E. David Burt, JP, MP, at an Executive Forum in London this month to highlight the historic and successful economic relationship that exists between Bermuda, the U.S. and the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005627/en/ Bermuda Executive Forum London 2019 opening panel. (Photo: Business Wire) The keynote conversation between Ambassador Johnson, Sir Nicholas Soames and the Premier will explore the implications of global trends, address key challenges from Brexit to U.S. tax reform, and shed light on new opportunities to further develop economic ties. The discussion will be moderated by Fiona Luck, a Non-Executive Director on the Lloyd’s of London Franchise Board,

Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland Receive Planview Vision Awards13.11.2019 19:01:00 EETPress release

Over 700 attendees came together at Planview Horizons 2019 to connect, collaborate, and celebrate with their industry peers. This year, Advance Auto Parts, Blue Cross NC, Emory Healthcare, Johnsonville, Parkview Health, and Royal Bank of Scotland were the recipients of Planview Vision Awards for transformational leadership and excellence. “There are many remarkable business transformation journeys that our customers have undertaken leveraging Planview solutions,” said Marc Cannon, Planview chief customer officer. “We were honored at this year’s Planview Horizons to celebrate these six visionary organizations for their commitment to, and success in, achieving their strategic goals.” Advance Auto Parts To address the industry trends around increased use of ridesharing, electric cars, and autonomous vehicles, a few “hidden innovators” at Advance Auto Parts set out to generate and collaborate on new ideas that would disrupt the market and delight their customers. With Planview Spigit™, Adv

Mercatus Selected as Finalist for REFI US Award for Portfolio Management13.11.2019 17:00:00 EETPress release

Mercatus, the data and technology platform for private market investors, today announced it has been shortlisted as a finalist for the 2019 REFI US Award for Portfolio Management. The REFI US Awards reward real estate private equity funds and service providers for outstanding performance and overall excellence. “We understand the unique challenges of real estate investing in harnessing very disparate data for critical risk and performance insights,” said Haresh Patel, CEO of Mercatus. “We purposefully built a modern data-driven architecture that starts at the site- and asset-level and then rolls up to fund/portfolio levels. We believe it’s the only way to truly understand and measure each investment. It’s very rewarding to be recognized by REFI US for the innovation we’ve brought to this sector.” REFI US award winners are selected through a rigorous two-stage judging process using both performance metrics as well as qualitative factors. Factors used by judges in the “PropTech” category

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom